Host-pathogen Interactions in Meningococcal Disease: Finding the Key That Fits the Lock
NCT02727465 · Status: WITHDRAWN · Type: OBSERVATIONAL
Last updated 2017-04-05
Summary
At any time, around 10% of people carry meningococcal bacteria in the nose and throat, which can cause meningitis, blood poisoning and other serious illnesses. Most people carry these bacteria and never become ill, yet a very small proportion go on to develop these illnesses which can result in life long disabilities or death. The mechanism by which this happens is poorly understood and has been studied in various ways, usually focussing on the bacteria or on the individual, but none has given a definitive answer. This study will be the first of its kind and will assess the interaction between the host and the bacteria at the genetic level, through genetic mapping, helping us to understand what makes some people susceptible to this infection.
Conditions
Interventions
- OTHER
-
Meningitis cases
None - blood draw only
Sponsors & Collaborators
-
Public Health England
lead OTHER_GOV
Principal Investigators
-
Shamez Ladhani, MD PhD · Public Health England
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-03-31
- Primary Completion
- 2019-12-31
- Completion
- 2019-12-31
Countries
- United Kingdom
More Related Trials
-
Evaluation of Meningococcal ACWY Immune Response in Children Aged 40 and 60 Months
NCT00601731 ·Status: COMPLETED ·Phase: PHASE2
-
Study on the Impact of Vaccination With a Conjugate Vaccine on Meningococcal Carriage
NCT01119482 ·Status: COMPLETED ·Phase: PHASE4
-
Understanding the Immune Response to Meningitis Vaccines
NCT00901940 ·Status: COMPLETED ·Phase: PHASE3
-
Defining the Immune Response to Nasopharyngeal Colonisation by the Commensal Neisseria Lactamica
NCT03633474 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Immunogenicity and Safety of Meningococcal (A, C, Y and W135) Conjugate Vaccine
NCT02003495 ·Status: COMPLETED ·Phase: PHASE3
-
Persistence and Booster Study of GSK Biologicals' Meningococcal Vaccine (GSK134612) in Healthy Children
NCT01266993 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine
NCT00856297 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants
NCT00806195 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of GSK Biologicals' Meningococcal Vaccine (GSK134612) and Licensed MenC-CRM197 Vaccine in Healthy Children
NCT00674583 ·Status: COMPLETED ·Phase: PHASE3
-
A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years
NCT01352793 ·Status: COMPLETED ·Phase: PHASE3
-
Antibody Responses Following Meningococcal Tetravalent (A, C, Y, and W-135) Conjugate Vaccination in Healthy Adults
NCT00772629 ·Status: TERMINATED ·Phase: PHASE2
-
Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents
NCT02140762 ·Status: COMPLETED ·Phase: PHASE2
-
Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Infants
NCT00262002 ·Status: COMPLETED ·Phase: PHASE2
-
Immunogenicity of Quadrivalent Meningococcal Conjugate Vaccine in Frequent Platelets Donors
NCT04224311 ·Status: UNKNOWN ·Phase: PHASE4
-
Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old Toddlers.
NCT00471081 ·Status: COMPLETED ·Phase: PHASE2
-
National Bacterial Meningitis Study in Children and Newborns
NCT04664569 ·Status: RECRUITING
-
B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants
NCT00488683 ·Status: COMPLETED ·Phase: PHASE2
-
Safety, Tolerability and Immunogenicity of Two Different Formulations of Meningococcal B Recombinant Vaccine, When Administered to Healthy Infants
NCT00433914 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluate 4 Different Formulations of Meningococcal Serogroups A, C, W-135, Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 15-19 Yrs
NCT00196963 ·Status: COMPLETED ·Phase: PHASE2
-
Understanding the Persistence of Immunity After MenC Vaccines
NCT01126996 ·Status: COMPLETED
-
Understanding the Immune Response to Two Different Meningitis Vaccines
NCT01593514 ·Status: COMPLETED ·Phase: PHASE4
-
A Case-control Study of the Efficacy of a New Serogroup A Meningococcal Conjugate Vaccine (MenAfriVac) in Mali and Niger
NCT01303211 ·Status: WITHDRAWN
-
Comparison of Two Meningococcal ACWY Conjugate Vaccines
NCT01192997 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Study to Evaluate Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 18-25 Years
NCT00196950 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Persistence and Immune Response to a Booster Dose of MenACWY
NCT01018732 ·Status: COMPLETED ·Phase: PHASE2